Compare Eli Lilly And Co (LLY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Tyson Foods, Inc. — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Tyson Foods, Inc. trades at $53.41 (market cap $18.41B). The key difference: Eli Lilly And Co is far larger — about 56.5× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Tyson Foods, Inc. for 76 Days on average.
| LLY | TSN | |
|---|---|---|
Market Cap | $1.04T | $18.41B |
Volume | 3,064,878 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $68.75 |
52-Week Low | $799.57 | $50.47 |
Typical Hold Time | 93 Days | 76 Days |
Enterprise Value | $1.09T | $25.68B |
Dividend Yield | 0.59% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Tyson Foods (TSN) trades at $53.43, up 3.35% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, but faces challenges with thin 1.03% net margins and ongoing beef segment losses. Recent news highlights securities investigations and reduced 2026 revenue guidance, creating investor uncertainty despite institutional buying activity.
The stock presents a cautious opportunity with analyst consensus target of $65.40 (22% upside) but faces significant headwinds from margin pressure and legal scrutiny. Key risks include beef segment profitability, potential securities violations, and volatile cash flow patterns. Upside depends on operational improvements and resolution of ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
